Targeting RSK, Chk2, and related pathways raises hemoglobin and restores erythroid differentiation in ribosomal protein deficient cells.
Targeting LRRC8 channels with modulators such as DCPIB inhibits platelet activation and thrombosis while limiting bleeding risk.